Inhibikase shares surge 12.5% premarket after FDA designations and strategic shift to PAH-focused IkT-001Pro trials.

Inhibikase Therapeutics surged 12.5% in premarket trading following positive developments linked to regulatory milestones and strategic realignment. The stock gained momentum as the company announced favorable FDA designations for its programs and shifted focus toward its lead candidate, IkT-001Pro, for pulmonary arterial hypertension (PAH). This shift includes pausing Parkinson’s drug development to prioritize PAH, with the global Phase 3 "IMPROVE-PAH" trial slated to begin in Q1 2026. Investors reacted favorably to the strategic refocusing and allocation of capital toward high-potential ventures, despite underlying financial challenges such as negative pretax margins. The FDA-related optimism and renewed emphasis on a scalable therapeutic area appear to have driven the premarket rally.